Castellano | Euskara | Français | English
DAR No 3: Albiglutide. Eperzan® for type 2 diabetes mellitus
Share it
No weight loss, no use
- Albiglutide is a once-weekly GLP- 1 analog. In Spain, it is only reimbursed when administered in combination with other glucoselowering medicinal products and weight loss is not required.
- Studies have not proven non-inferiority vs liraglutide in reducing HbA1c. No comparative studies have been performed with exenatide once weekly.
- Effectiveness data in terms of morbi-mortality are not available.
- It has a neutral effect on weight, in contrast with other drugs of the same family that help lose weight.
- The profile of adverse effects of albiglutide seems to be similar to that of other GLP-1 analogs. The incidence of nausea and vomiting is lower in albiglutide than in liraglutide.
- Long-term safety is unknown. There is concern about the associated risk of pancreatitis, pneumonia, cardiovascular disease, and pancreatic and thyroid tumors.
